Everolimus Stent in Patients With Coronary Artery Disease (CAD) (RACES)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Aim of the study is to compare the everolimus eluting stent and sirolimus eluting stent in all comers PCI eligible patients
Condition | Intervention | Phase |
---|---|---|
Coronary Artery Disease Coronary Atherosclerosis |
Device: coronary stent Device: stent |
Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | Randomized Comparison of Everolimus Eluting Stents and Sirolimus Eluting Stent in Patients With Coronary Artery Disease |
- Target Vessel Revascularization [ Time Frame: 2 year ] [ Designated as safety issue: No ]Incidence of clinically driven target vessel revascularization at 2 year follow up
- cardiac death [ Time Frame: 2 year ] [ Designated as safety issue: No ]incidence of death for cardiac causes at 2 year
- non fatal myocardial infarction [ Time Frame: 2 year ] [ Designated as safety issue: No ]incidence of non fatal Q or non Q wave reinfarction at 2 year
- stent thrombosis [ Time Frame: 2 year ] [ Designated as safety issue: Yes ]incidence of definite, probable or possible stent thrombosis at 2 year
Enrollment: | 600 |
Study Start Date: | March 2007 |
Study Completion Date: | June 2010 |
Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: EES Group
Patients who received an everolimus eluting stent
|
Device: coronary stent
coronary angioplasty with stent implantation
Other Name: XIENCE V drug eluting stent; Abbot Vascular USA
|
Active Comparator: SES Gruop
Patients who received a sirolimus eluting stent
|
Device: stent
coronary angioplasty with stent implantation
Other Name: CYPHER drug eluting stent; Johnson & Johnson USA
|
Detailed Description:
Compared with the currently available first-generation drug-eluting stents (DES), second-generation DES have been designed with the goal of improving safety and efficacy. Everolimus, a sirolimus analogue, is released from a open cell, thin-strut, cobalt-chromium frame. A significant reduction in cardiac events was noted in patients with the everolimus-eluting stent compared with those who had a paclitaxel-eluting stent. Sirolimus eluting stent was the first available drug eluting stent and is the most tested. Therefore the investigators compared the safety and efficacy of the everolimus-eluting and sirolimus eluting stents in unselected patients in real world practice.
Ages Eligible for Study: | 18 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- All patients with coronary artery disease eligible for percutaneous coronary intervention (PCI)
Exclusion Criteria:
- Contraindication to dual antiplatelet therapy for 12 months
- Known allergy to sirolimus or everolimus
- Major surgical procedure planned within 1 month
- History, symptoms, or findings suggestive of aortic dissection.
- Participation in other trials
- Pregnancy
Italy | |
Division of Cardiology Aorn Moscati | |
Avellino, Italy, 83100 |
Principal Investigator: | EMILIO DI LORENZO, MD PhD | DIVISION OF CARDIOLOGY AORN MOSCATI AVELLINO ITALY |
Publications:
Responsible Party: | EMILIO DI LORENZO MD PhD, DIVISION OF CARDIOLOGY AO MOSCATI |
ClinicalTrials.gov Identifier: | NCT01182649 History of Changes |
Other Study ID Numbers: | AOM_DES02 |
Study First Received: | August 9, 2010 |
Last Updated: | August 16, 2010 |
Health Authority: | Italy: Ethics Committee |
Keywords provided by San Giuseppe Moscati Hospital:
Drug Eluting Stents Everolimus Eluting Stent Coronary Angioplasty |
Additional relevant MeSH terms:
Atherosclerosis Coronary Artery Disease Myocardial Ischemia Coronary Disease Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Cardiovascular Diseases Heart Diseases Sirolimus Everolimus |
Antibiotics, Antineoplastic Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Antifungal Agents Anti-Infective Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Anti-Bacterial Agents |
ClinicalTrials.gov processed this record on October 17, 2012